These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 31482502)
1. Enzybiotics: Enzyme-Based Antibacterials as Therapeutics. Dams D; Briers Y Adv Exp Med Biol; 2019; 1148():233-253. PubMed ID: 31482502 [TBL] [Abstract][Full Text] [Related]
2. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. Gerstmans H; Rodríguez-Rubio L; Lavigne R; Briers Y Biochem Soc Trans; 2016 Feb; 44(1):123-8. PubMed ID: 26862197 [TBL] [Abstract][Full Text] [Related]
3. Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens. Briers Y; Walmagh M; Van Puyenbroeck V; Cornelissen A; Cenens W; Aertsen A; Oliveira H; Azeredo J; Verween G; Pirnay JP; Miller S; Volckaert G; Lavigne R mBio; 2014 Jul; 5(4):e01379-14. PubMed ID: 24987094 [TBL] [Abstract][Full Text] [Related]
4. Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. Danis-Wlodarczyk KM; Wozniak DJ; Abedon ST Antibiotics (Basel); 2021 Dec; 10(12):. PubMed ID: 34943709 [TBL] [Abstract][Full Text] [Related]
5. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Briers Y; Lavigne R Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461 [TBL] [Abstract][Full Text] [Related]
7. Bacteriophage endolysins as a novel class of antibacterial agents. Borysowski J; Weber-Dabrowska B; Górski A Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria. Liu H; Hu Z; Li M; Yang Y; Lu S; Rao X J Biomed Sci; 2023 Apr; 30(1):29. PubMed ID: 37101261 [TBL] [Abstract][Full Text] [Related]
9. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Hermoso JA; García JL; García P Curr Opin Microbiol; 2007 Oct; 10(5):461-72. PubMed ID: 17904412 [TBL] [Abstract][Full Text] [Related]
10. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy. Oliveira H; São-José C; Azeredo J Viruses; 2018 May; 10(6):. PubMed ID: 29844287 [TBL] [Abstract][Full Text] [Related]
13. Metagenomic analysis of hot spring soil for mining a novel thermostable enzybiotic. Pantiora PD; Georgakis ND; Premetis GE; Labrou NE Appl Microbiol Biotechnol; 2024 Jan; 108(1):163. PubMed ID: 38252132 [TBL] [Abstract][Full Text] [Related]
14. The Advantages and Challenges of Using Endolysins in a Clinical Setting. Murray E; Draper LA; Ross RP; Hill C Viruses; 2021 Apr; 13(4):. PubMed ID: 33920965 [TBL] [Abstract][Full Text] [Related]
16. Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs. Mirski T; Lidia M; Nakonieczna A; Gryko R Ann Agric Environ Med; 2019 Jun; 26(2):203-209. PubMed ID: 31232046 [TBL] [Abstract][Full Text] [Related]
17. Phages and Enzybiotics in Food Biopreservation. Ramos-Vivas J; Elexpuru-Zabaleta M; Samano ML; Barrera AP; Forbes-Hernández TY; Giampieri F; Battino M Molecules; 2021 Aug; 26(17):. PubMed ID: 34500572 [TBL] [Abstract][Full Text] [Related]
18. The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole. Abdelkader K; Gerstmans H; Saafan A; Dishisha T; Briers Y Viruses; 2019 Jan; 11(2):. PubMed ID: 30678377 [TBL] [Abstract][Full Text] [Related]